Core Insights - Cognition Therapeutics is making significant advancements in developing treatments for neurodegenerative diseases, particularly focusing on zervimesine (CT1812) for dementia with Lewy bodies (DLB) and Alzheimer's disease [2][4][5] Company Progress - The company has reported strong results from the Phase 2 SHIMMER trial for zervimesine in DLB, showing favorable impacts across various symptom domains, particularly in neuropsychiatric inventory assessments [3][5] - The Phase 2 START study, which includes 545 participants with mild cognitive impairment (MCI) and early Alzheimer's disease, is fully enrolled and expected to provide data readouts in the second half of 2027 [7] Clinical Trials and Regulatory Engagement - The FDA has aligned with the company's Phase 3 program design for zervimesine, focusing on participants with low levels of p-tau217, which is associated with a significant reduction in cognitive decline [6][5] - The company plans to meet with the FDA's Division of Psychiatry in Q2 2026 to discuss the registrational plan for zervimesine in treating DLB psychosis [4] Financial and Funding Aspects - The START trial is fully funded by an NIH grant, ensuring that costs are covered through the study's completion in 2027 [7] - Cognition Therapeutics has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its research efforts [9] Future Outlook - The company expresses confidence that the achievements of 2025 will propel zervimesine closer to providing effective treatment options for patients in 2026 [8]

Core Insights - Anavex Life Sciences Corp. is advancing the development program of oral blarcamesine for early Alzheimer's disease and is in discussions with the European Medicines Agency (EMA) and U.S. FDA regarding regulatory pathways for its approval [1][2][3] Regulatory Developments - Following the withdrawal of the marketing authorization application for blarcamesine in the EU, the company is gathering additional data to address concerns raised by the Committee for Medicinal Products for Human Use (CHMP) [2] - Anavex has submitted additional data to the U.S. FDA to align on the Alzheimer's disease development program for blarcamesine [3] Clinical Focus - The company is also engaging with EU regulators for blarcamesine's use in Parkinson's disease and rare neurological conditions, highlighting the breadth of its clinical development portfolio [3] - Blarcamesine has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [6] Product Profile - Blarcamesine is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease progression [6] - The drug candidate has demonstrated various properties, including anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant effects in animal models, suggesting its potential for treating additional CNS disorders [6]

Financial Data and Key Metrics Changes - Cash, cash equivalents, and restricted cash equivalents as of December 31, 2025, were approximately $37 million, with total grant funds remaining from the NIA at $35.7 million [17] - Research and development expenses were $37.2 million for the year ended December 31, 2025, compared to $41.7 million for 2024, reflecting a decrease due to the completion of clinical trials [18] - General and administrative expenses were $10.6 million for the year ended December 31, 2025, down from $12.3 million in 2024, primarily due to reduced stock-based compensation [18] - The company reported a net loss of $23.5 million, or $0.32 per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34 million, or $0.86 per share for 2024 [18][19] Business Line Data and Key Metrics Changes - The primary focus remains on the development of zervimesine (CT-1812) for neurodegenerative diseases, with significant progress in clinical trials for dementia with Lewy bodies (DLB) and Alzheimer's disease [4] - The phase II SHIMMER study in DLB showed zervimesine had an 86% slowing of progression in neuropsychiatric symptoms compared to placebo [6] - The phase II SHINE study in mild to moderate Alzheimer's disease demonstrated a 38% reduction in cognitive decline on the ADAS-Cog 11 scale [14][15] Market Data and Key Metrics Changes - The company is prioritizing the development of zervimesine for DLB psychosis, a condition with no approved medications, where psychosis is prevalent in up to 80% of DLB patients [8][9] - The company aims to expedite the path to market for zervimesine by focusing on psychosis, which is expected to allow for smaller and shorter registrational studies [10][11] Company Strategy and Development Direction - The company has decided to prioritize the development of zervimesine for DLB psychosis based on positive feedback from clinical trials and anecdotal evidence from patients [4][12] - The strategy includes seeking alignment with regulatory bodies like the FDA and EMA to ensure a smooth path for clinical trials and potential approval [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of zervimesine as a first-in-class treatment for DLB patients with psychosis, highlighting the lack of existing treatment options [49] - The company plans to meet with the FDA's Division of Psychiatry to finalize plans for studying DLB psychosis, indicating a proactive approach to regulatory engagement [49] Other Important Information - The expanded access program (EAP) for zervimesine has garnered significant interest from patients and families, indicating a strong demand for the treatment [13][14] - The company has sufficient cash to fund operations through the second quarter of 2027, ensuring financial stability for ongoing projects [17] Q&A Session Summary Question: Plans for partnership in ocular conditions - The company is currently focused on developing zervimesine for DLB and is not pursuing an ophthalmology program at this time [20][21] Question: Regulatory path for DLB program - The company intends to develop zervimesine for a label relating to psychosis in DLB and aims to move quickly through registrational trials, with details pending FDA meetings [24][25] Question: Updates on additional trials - The company is completing low-risk studies related to pharmacology and formulation changes, which are expected to be finished in 2026 [26][27] Question: Effect of zervimesine on Alzheimer's disease - The company is awaiting results from the START trial before prioritizing further development in Alzheimer's disease, while currently focusing on DLB [30][31] Question: Synergy with existing CNS medications - The company has conducted studies on standard care background medications and is collecting data on potential benefits of combination therapies [35][36] Question: Mechanism of action of zervimesine - The company believes zervimesine interrupts the basic pathophysiology of neurodegenerative diseases rather than directly impacting psychosis-related receptors [40][41] Question: Primary endpoint for DLB psychosis trial - The company has not finalized the study design for the DLB psychosis trial, but secondary measures will include cognition and other symptom domains [43][44]

Core Viewpoint - NeuroSense Therapeutics is advancing its lead asset, PrimeC, towards key regulatory milestones with a strengthened data package and expects to report clinical results for Alzheimer's disease soon [1][3]. Regulatory Updates - A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026 to include additional clinical, biomarker, and survival data [2]. - The company aims to advance PrimeC under the NOC/c pathway in Canada, facilitating earlier access to therapies for serious unmet medical needs [3]. Clinical Program Developments - NeuroSense anticipates reporting clinical and biomarker results from its Alzheimer's study in the coming weeks [3]. - The company is focused on presenting a comprehensive dataset to Health Canada to enhance the likelihood of a constructive regulatory pathway [3]. Product Information - PrimeC is a novel extended-release oral formulation combining ciprofloxacin and celecoxib, targeting mechanisms of ALS and Alzheimer's disease [6]. - The drug has shown a statistically significant survival benefit, with a 65% reduction in the risk of death [6]. Market Context - Neurodegenerative diseases, including ALS and Alzheimer's, represent significant unmet medical needs, with limited effective therapeutic options available [4]. - The annual disease burden of ALS in the U.S. is approximately $1 billion, with over 5,000 new diagnoses each year [8].

Core Insights - NeuroSense Therapeutics is advancing its investigational therapy PrimeC for amyotrophic lateral sclerosis (ALS) and will present new data at the AD/PD 2026 conference [1][2] Company Overview - NeuroSense Therapeutics is a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease [5] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options [5] Product Information - PrimeC is a novel extended-release oral formulation that combines two FDA-approved drugs: ciprofloxacin and celecoxib, targeting multiple mechanisms associated with ALS and Alzheimer's disease [7] - The therapy is designed to potentially inhibit the progression of ALS and Alzheimer's disease by addressing neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation [7] Clinical Trials - Dr. Christian Lunetta will present findings from the Phase 2b PARADIGM trial, which evaluated PrimeC in ALS patients, at the AD/PD 2026 conference [2][3] - The PARADIGM trial results provide insights into disease mechanisms and treatment effects, informing the design of the upcoming global Phase 3 PARAGON trial [2][3] - The PARAGON trial is planned as a multinational, randomized, double-blind, placebo-controlled study to further evaluate PrimeC's safety and efficacy in slowing disease progression in ALS patients [3] Market Context - ALS is an incurable neurodegenerative disease that leads to complete paralysis and death within 2-5 years from diagnosis, with over 5,000 new cases diagnosed annually in the U.S. [8] - The annual disease burden of ALS in the U.S. is approximately $1 billion, and the number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU [8]

Core Insights - Alterity Therapeutics has appointed Dr. Daniel O. Claassen as Chief Medical Advisor, effective March 2026, bringing extensive expertise in neurodegenerative diseases to the company [1][3] Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) [4] - The company is preparing to initiate a Phase 3 pivotal trial for its lead asset, ATH434, which has shown clinically meaningful efficacy in Phase 2 trials [4] Dr. Claassen's Background - Dr. Claassen is a board-certified neurologist with over 20 years of experience in clinical and translational research related to movement disorders and cognitive neurology [2] - He has authored hundreds of peer-reviewed publications and has been a principal investigator in numerous clinical trials, contributing significantly to the advancement of therapies for neurodegenerative disorders [2] Strategic Importance - The appointment of Dr. Claassen is seen as pivotal for Alterity as it advances ATH434 into Phase 3 trials, with his previous involvement in the Phase 2 study enhancing his qualifications to guide the company's growth [3] - Dr. Claassen's focus on translating academic research into clinical applications aligns with the urgent need for disease-modifying therapies in neurodegenerative diseases [3]

Core Insights - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company focused on developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1][6] - The company announced two presentations at the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026), scheduled for March 17-21, 2026, in Copenhagen, Denmark [1][2] Presentation Highlights - The presentations will showcase clinical data supporting the treatment effect of buntanetap in PD, emphasizing cognition and biomarker findings, along with an update on the ongoing pivotal Phase 3 trial in early AD [2][4] - Cheng Fang, Ph.D., Senior VP of Research & Development, expressed pride in the progress of enrollment for the Alzheimer's disease pivotal study, indicating strong engagement from investigators and patients [4] Company Overview - Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments for neurodegenerative diseases, with its lead drug candidate, buntanetap, being an investigational once-daily oral therapy [6] - Buntanetap works by inhibiting the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism, aiming to halt disease progression and improve cognitive and motor functions in patients [6]

Core Insights - AB Science has identified a plasma biomarker that indicates the activity of masitinib in treating Amyotrophic Lateral Sclerosis (ALS) and can identify patients with pro-inflammatory microglia, which are targeted by masitinib [1][2] - This biomarker is also applicable to progressive forms of Multiple Sclerosis (MS) and Alzheimer's disease, potentially enhancing treatment response identification and registration chances in neurodegenerative diseases [1][2] Biomarker Characteristics - The biomarker is blood-based, easy to collect, and can be accurately evaluated using ELISA [4] - It is produced by pro-inflammatory microglia, activates microglia and astrocytes, and contributes to a neuroinflammation feedback loop [4] - It is predictive of survival in ALS, potentially explaining why masitinib could extend survival in specific patients [4] Clinical Development - The biomarker will be introduced in the phase 3 program of masitinib for ALS, progressive MS, and Alzheimer's disease to validate its mechanism of action and clinical relevance [3] - Once validated, it could facilitate patient registration by determining the best responders to treatment and serve as a surrogate endpoint of efficacy [3] Regulatory Context - The FDA encourages the incorporation of exploratory biomarkers in all phases of ALS drug development, which may lead to discussions on surrogate endpoints for accelerated approval [3]

Core Insights - MediciNova, Inc. has successfully completed patient enrollment in the Phase 2 clinical trial, OXTOX study, evaluating MN-166 (ibudilast) for preventing chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [1][2] Group 1: Clinical Trial Details - The OXTOX study is a randomized, placebo-controlled trial with 100 patients enrolled across 11 clinical sites in Australia [1] - Participants will continue chemotherapy along with either MN-166 or placebo until disease progression or unacceptable side effects, with the study concluding when the final patient reaches six months post-chemotherapy [2] Group 2: About MN-166 (ibudilast) - MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, currently in late-stage clinical development for various neurodegenerative diseases, including ALS and progressive MS [3] - The compound has Orphan Drug Designation and Fast Track Status from the US FDA for ALS, and Orphan Drug Designation from the EMA [3] Group 3: About MediciNova - MediciNova is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [4] - The company has a strong pipeline, with MN-166 in Phase 3 for ALS and DCM, and MN-001 (tipelukast) in Phase 2 for treating hypertriglyceridemia in type 2 diabetic patients [4]

Core Viewpoint - ProMIS Neurosciences, Inc. is actively engaging with investors and the healthcare community through participation in the 8th Annual Evercore Healthcare Conference, highlighting its focus on developing innovative therapies for Alzheimer's disease and other neurodegenerative disorders [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic antibodies and vaccines that target toxic oligomers associated with neurodegenerative diseases, including Alzheimer's disease, ALS, FTD, MSA, and PD [3]. - The company utilizes its proprietary EpiSelect™ target discovery engine to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are crucial for developing targeted therapies [3]. Product Development - PMN310 is the lead product candidate designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [4]. - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential significance in treating Alzheimer's disease [4]. Clinical Trials - Following positive results from the Phase 1a trial, ProMIS initiated the PRECISE-AD Phase 1b clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [5]. - The PRECISE-AD trial is designed as a randomized, double-blind, placebo-controlled study, focusing on the effects of PMN310 on biomarkers and clinical outcomes associated with Alzheimer's disease [5]. EpiSelect Drug Discovery Engine - The EpiSelect platform enables the identification of conformational epitopes on toxic misfolded proteins, facilitating the development of highly selective therapeutic antibodies and vaccines [6]. - PMN310 has demonstrated high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing adverse effects associated with conventional therapies [6].